A Comparative Study of JNS013 in Participants With Post-Tooth-Extraction Pain
Launched by JANSSEN PHARMACEUTICAL K.K. · Aug 15, 2008
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
This is a multi-center (conducted in more than one center), double-blind (neither Physician nor participant knows the name of the assigned drug), randomized (study drug assigned by chance), parallel-group (each group of participant will be treated at the same time) and comparative study in participants having pain intensity of at least 50.0 millimeter (mm) (on visual analog scale, score ranging from 0 mm \[no pain\] to 100 mm \[worst possible pain\]), following extraction of an impacted mandibular wisdom tooth. The study consists of 3 parts: Pre-observation (7 days before study commences on...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants planned to receive a tooth extraction of one mandibular impacted wisdom tooth
- • Participants who require bone removal and separation of the crown at tooth extraction
- • Participants whose intensity of pain associated with tooth extraction within 2 hours after tooth extraction is greater than or equal to 50.0 millimeter on the visual analog scale (VAS)
- • Participants who did not undergo general anesthesia or sedation at tooth extraction
- • Participants without an abnormality (including laboratory test values) corresponding to Grade 3 in the "Criteria for severity classification of adverse drug reactions" during the pretreatment observation period
- Exclusion Criteria:
- • Participants with conditions for which tramadol is contraindicated
- • Participants with conditions for which acetaminophen is contraindicated
- • Participants with history of convulsions or the possibility of convulsive seizures
- • Pregnant participants or those who may be pregnant, lactating mothers, and those who wish pregnancy during the study period
- • Participants with concurrent, previous, or possible alcohol dependence, drug dependence or narcotic addiction
About Janssen Pharmaceutical K.K.
Janssen Pharmaceutical K.K., a subsidiary of Johnson & Johnson, is a leading global pharmaceutical company committed to addressing some of the most pressing healthcare challenges through innovative research and development. With a strong focus on therapeutic areas including immunology, infectious diseases, neuroscience, oncology, and cardiovascular health, Janssen Pharmaceutical K.K. leverages cutting-edge science and technology to deliver transformative treatments. The company is dedicated to advancing medical knowledge and improving patient outcomes through robust clinical trials and collaborations with healthcare professionals, researchers, and institutions worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokyo, , Japan
Kumamoto, , Japan
Osaka, , Japan
Kitakyushu, , Japan
Sapporo, , Japan
Yokohama, , Japan
Yokosuka, , Japan
Isehara, , Japan
Shimotsuke, , Japan
Ohta Ku, , Japan
Shimotsuga, , Japan
Yokohama N/A, , Japan
Patients applied
Trial Officials
Janssen Pharmaceutical K.K., Japan Clinical Trial
Study Director
Janssen Pharmaceutical K.K.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials